AL-ADTRAN
Adtran today launched a major upgrade of its Oscilloquartz aPNT+™ technology suite, bringing new levels of resilience to critical network infrastructure that relies on position, navigation and timing (PNT) services. With enhancements to its core, edge and access synchronization solutions, the portfolio provides operators of telecommunications, financial networks, power grids, defense infrastructure and more with the best available protection against GNSS vulnerabilities and cyberattacks. Adtran’s timing technology now leverages more sources of accurate and reliable timing and features new capabilities to detect disturbances and assure vital PNT services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230512005309/en/
Adtran’s Oscilloquartz aPNT+™ platform is a vital tool for keeping critical infrastructure safe and online. (Photo: Business Wire)
“From 5G connectivity to air traffic control, accurate and reliable PNT services are crucial for the safety, efficiency and optimal performance of a wide range of modern applications. That’s why the enhancements we’ve made to our aPNT+™ platform are so significant. These include improved jamming and spoofing detection using a unique, highly advanced, dedicated algorithm to ensure maximum resilience against any intentional or unintentional interference,” said Igal Pinhasov, VP of product line management at Oscilloquartz, Adtran. “Our upgraded portfolio is a significant step up for critical network timing. It provides unparalleled precision and reliability even in the most challenging environments, including situations where GNSS is disrupted for extended periods.”
Adtran’s OSA 5401 and 5405 access network synchronization solutions now feature the same advanced jamming and spoofing detection capabilities as its core and edge products. Additionally, the OSA 5405-MB, a compact and integrated outdoor multi-band GNSS receiver and PTP grandmaster, has been upgraded with improved multi-band capabilities. As well as satellite constellations, including GPS, GLONASS, BeiDou and GALILEO, it now supports the Indian Regional Navigation Satellite System (IRNSS). This is critical for mobile network operators in the subcontinent, as the Indian government has ruled that smartphones must be compatible with the country’s home-grown GNSS system. Furthermore, the solution now utilizes a combination of L1 and L5 band signals to better mitigate disruption caused by environmental factors.
“Enhanced NTP functionality is another feature that makes our upgraded aPNT+™ platform even more powerful. Our standalone NTP servers can now support up to 500,000 transactions per second, providing unique NTP performance. This level of transaction handling is a significant advantage against DDoS attacks,” commented Gil Biran, GM of Oscilloquartz, Adtran. “Our core and edge grandmaster clocks are also more resilient than ever. With our multi-source ePRTC combiner, they can leverage up to five independent timing sources, which can include up to three high-performance optical cesium atomic clocks, to create a single super-resilient and highly reliable clock source. Customers can select from GNSS constellations, PTP inputs, and alternative PNT sources such as STL, which uses low Earth orbit satellites, or the terrestrial-based eLORAN. Both offer extra protection against jamming and spoofing attacks while extending the 100nsec holdover period.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of ADVA. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230512005309/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1GLOBAL Empowers Revolut to Offer Mobile Plans in Poland16.12.2025 13:04:00 CET | Press release
1GLOBAL, a technology-driven global mobile communications provider, strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216769985/en/ 1GLOBAL strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. By integrating 1GLOBAL’s eSIM capability into its multi-service app, Revolut’s customers in Poland who signed up to the waitlist can now enjoy bundled mobile plans that include competitively priced domestic data plans starting at zł 25 per month (approx. €6.00 per month) with unlimited calls and texts in Poland and the EU, in just a few taps. For 1GLOBAL, this expansion marks another milestone in the company’s embedded telco services strategy. The services are trusted by more than 4,000 corporate partners across a variety of industries including fi
Dompé Doses First Patients in Europe and US in Phase 3 Studyof Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press release
Atopic keratoconjunctivitis(AKC) is a chronic inflammatory disease of the eye that is frequently associated with atopic conditions, and limited disease awareness often leads to delayed or missed diagnosis. Isocyclosporin is a novel, dual inhibitor oftwo critical immunepathways in ocular inflammation like AKC. Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment
Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration16.12.2025 13:00:00 CET | Press release
With more than $3.5B in annualized stablecoin settlement volume1, Visa brings USDC settlement to U.S. institutions. Visa Inc. (V) today announced the launch of USDC settlement in the United States, marking a major milestone in the company’s stablecoin settlement pilot program and strategy to modernize its settlement layer underpinning global commerce. For the first time, U.S. issuer and acquirer partners can settle with Visa in Circle’s USDC, a fully reserved, dollar-denominated stablecoin. With USDC settlement, issuers can benefit from faster funds movement over blockchains, seven‑day availability and enhanced operational resilience across weekends and holidays - without any change to the consumer card experience. Initial banking participants include Cross River Bank and Lead Bank, which have started settling with Visa in USDC over the Solana blockchain. Broader availability in the U.S. is planned through 2026. Additionally, Visa is a design partner for Arc, a new Layer 1 blockchain d
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release
PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom